Skip to main content
رجوع
SLS logo

SELLAS Life Sciences Group, Inc.

جودة البيانات: 100%
SLS
NASDAQ Healthcare Biotechnology
KWD 5.48
▲ KWD 0.72 (15.13%)
القيمة السوقية: 780.58M
نطاق اليوم
KWD 4.84 KWD 5.50
نطاق 52 أسبوعًا
KWD 0.95 KWD 6.14
حجم التداول
9,916,235
متوسط 50 يوم / 200 يوم
KWD 4.44 / KWD 2.54
الإغلاق السابق
KWD 4.76

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -29.1 0.4
P/B 11.0 2.9
ROE % -66.9 3.7
Net Margin % — 3.9
Rev Growth 5Y % — 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 2.800 -48.9%
Low: KWD 2.400 High: KWD 3.200
ربحية السهم المستقبلية
-KWD 0.283
الإيرادات المقدّرة
36 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 3.650
KWD 3.495 – KWD 3.805
 580 M 1
FY2029 KWD 1.850
KWD 1.771 – KWD 1.929
 320 M 1
FY2028 KWD 0.003
-KWD 0.250 – KWD 0.300
 120 M 3

Insider Trading Activity

14 transactions
Date Insider Type Shares Price Value
Jan 7, 2026
CICIC DRAGAN
SVP, Chief Development Officer
 grant 300,000 — —
Jan 7, 2026
SCHEINBERG DAVID A
Director
 grant 50,000 — —
Jan 7, 2026
Wasman Jane
Director
 grant 50,000 — —
Jan 7, 2026
Varian John
Director
 grant 50,000 — —
Jan 7, 2026
Burns John Thomas
CFO
 grant 300,000 — —
Jan 7, 2026
VAN NOSTRAND ROBERT L
Director
 grant 50,000 — —
Jan 7, 2026
Kalin Katherine Bach
Director
 grant 50,000 — —
Dec 3, 2025
Stergiou Angelos M.
President and CEO
 other 187,066 KWD 1.500 KWD 280,599
Dec 3, 2025
CICIC DRAGAN
SVP, Chief Development Officer
 other 63,800 KWD 1.500 KWD 95,700
Dec 3, 2025
Burns John Thomas
CFO
 other 58,592 KWD 1.500 KWD 87,888
Nov 19, 2025
Kalin Katherine Bach
Director
 buy 63,400 KWD 1.590 KWD 100,806
Jun 12, 2025
VAN NOSTRAND ROBERT L
Director
 buy 10,000 KWD 1.480 KWD 14,800
May 30, 2025
Wasman Jane
Director
 buy 20,000 KWD 1.690 KWD 33,800
May 22, 2025
Kalin Katherine Bach
Director
 buy 20,000 KWD 1.800 KWD 36,000

النقاط الرئيسية

Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -28.39M
PEG of 0.31 suggests growth is underpriced

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-66.88%
ROIC-29.50%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
0.01
Current Ratio10.72
Interest Coverage0.00

التقييم

P/E Ratio
-29.06
P/B Ratio11.01
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -26.86M
ROE -66.88% ROA -34.29%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -28.39M
ROIC -29.50% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 10.72
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -29.06 P/B Ratio 11.01
P/S Ratio N/A PEG Ratio 0.31
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 780.58M Enterprise Value 709.69M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 1.00M 7.60M
Net Income -26.86M -30.88M -37.34M -41.30M -20.70M
EPS (Diluted) -0.25 -0.50 -1.34 -2.13 -1.34
Gross Profit 0.0 0.0 0.0 900,000.0 7.40M
Operating Income -28.27M -31.51M -37.87M -41.95M -25.29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 78.35M 19.43M 6.22M 20.94M 26.43M
Total Liabilities 7.47M 9.97M 14.20M 16.09M 6.08M
Shareholders' Equity 70.87M 9.47M -7.98M 4.85M 20.35M
Total Debt 1.00M 1.00M 906,000.0 945,000.0 808,000.0
Cash & Equivalents 71.89M 13.89M 2.53M 17.13M 21.46M
Current Assets 75.21M 16.33M 3.17M 17.76M 23.04M
Current Liabilities 7.02M 9.51M 13.74M 15.52M 4.98M